This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yuan, F. Articles by Jain, R. K. Search for Related Content PubMed PubMed Citation Articles by Yuan, F. Articles by Jain, R. K.

Pharmacokinetic Analysis of Two-Step Approaches Using Bifunctional and Enzyme-conjugated Antibodies¹

Tumor Microcirculation Laboratory, Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213-3890

Bifunctional antibodies (BFA) and enzyme-conjugated antibodies (ECA) can be used to preferentially deliver a hapten or drug to tumor sites for diagnosis and therapy. We present here a simple pharmacokinetic model for the above two systems by considering only two compartments, the plasma and tumor. The models predict that the longer the time delay between the BFA and hapten or between the ECA and prodrug injections, the higher the tumor:plasma concentration ratio of the hapten or drug. In addition, multiple injections of the hapten or prodrug is predicted to give a more uniform concentration of the hapten or drug in both the tumor and plasma than bolus injection. We suggest that, initially, the most effective dose of BFA should be selected and then the hapten concentration chosen accordingly. The decrease of the ECA injection dose would increase the tumor:plasma concentration ratio of the drug and yet decrease the tumor concentration of the drug. In clinical application of the ECA system, consideration of ECA dose should be balanced between the tumor concentration and the tumor:plasma concentration ratio of the drug. The dose of the prodrug injection is suggested to be equal to the required toxic concentration of the drug in the tumor. There are several ways to improve the tumor:plasma concentration ratio of the hapten or drug, such as changing the binding kinetics of the antibody to tumor or the hapten to BFA and removing the antibody from the plasma before the injection of the hapten or prodrug. One notable difference between the BFA and ECA approaches is that there is an upper limit for maximum hapten concentration in the former, and hence, from the point of drug delivery alone the latter approach is presumably superior. The limitations of the models and therapeutic implications are also discussed.

¹ Supported by grants from the National Cancer Institute (CA-36902 and CA-49792) and National Science Foundation (CBT-88-16062) and an Alexander von Humboldt Senior Scientist Award (1990–1991) to R. K. J.

² To whom requests for reprints should be addressed, at Tumor Microcirculation Laboratory, Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213-3890.

Received 12/26/90. Accepted 4/ 3/91.

This article has been cited by other articles:

				L. Fang and D. Sun Predictive Physiologically Based Pharmacokinetic Model for Antibody-Directed Enzyme Prodrug Therapy Drug Metab. Dispos., June 1, 2008; 36(6): 1153 - 1165. [Abstract] [Full Text] [PDF]

				S. K. Sharma, R. B. Pedley, J. Bhatia, G. M. Boxer, E. El-Emir, U. Qureshi, B. Tolner, H. Lowe, N. P. Michael, N. Minton, et al. Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy Clin. Cancer Res., January 15, 2005; 11(2): 814 - 825. [Abstract] [Full Text] [PDF]

				Y. Wang, J. K. Hu, A. Krol, Y.-P. Li, C.-Y. Li, and F. Yuan Systemic dissemination of viral vectors during intratumoral injection Mol. Cancer Ther., November 1, 2003; 2(11): 1233 - 1242. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, W. J. McBride, H. Karacay, K. Chang, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody Cancer Res., January 15, 2003; 63(2): 354 - 363. [Abstract] [Full Text] [PDF]

				L. A. Cavacini, M. Duval, J. P. Eder, and M. R. Posner Evidence of Determinant Spreading in the Antibody Responses to Prostate Cell Surface Antigens in Patients Immunized with Prostate-specific Antigen Clin. Cancer Res., February 1, 2002; 8(2): 368 - 373. [Abstract] [Full Text] [PDF]

				A. Krol, J. Maresca, M. W. Dewhirst, and F. Yuan Available Volume Fraction of Macromolecules in the Extravascular Space of a Fibrosarcoma: Implications for Drug Delivery Cancer Res., August 1, 1999; 59(16): 4136 - 4141. [Abstract] [Full Text] [PDF]

				D. Shabat, C. Rader, B. List, R. A. Lerner, and C. F. Barbas III Multiple event activation of a generic prodrug trigger by antibody catalysis PNAS, June 8, 1999; 96(12): 6925 - 6930. [Abstract] [Full Text] [PDF]